Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay. (March 2017) - Mamounas, E.P.; Goldstein, L.J.; Penault-Llorca, F.; Roché, H.; Gluz, O.; Harbeck, N.; Nitz, U.; O'shaughnessy, J.; Albain, K.S.